Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
Group 2 (luminal B). This type includes tumors that are ER positive, PR negative and HER2 positive.
Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2.
In fact, recent clinical trial data indicate that patients with hormone receptor-negative tumors (basal-like or HER2-positive) show better responses to adjuvant and neoadjuvant chemotherapy regimens than patients with luminal A and B tumors.
Patients who achieved a pCR had good prognosis regardless of tumor subtype; however, patients with basal-like or HER2-positive tumors who did not achieve pCR had a higher risk of relapse and poorer prognosis than other subgroups.
Group 3 (HER2 positive). This type includes tumors that are ER negative and PR negative, but HER2 positive.
HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2.
Group 4 (basal-like). This type, which is also called triple-negative breast cancer, includes tumors that are ER negative, PR negative and HER2 negative.
Basal-like breast cancers are likely to benefit from chemotherapy
Microtubule Stabilization
Ixabepilone:
a member of the epothilone class of macrolide antibiotics, possesses high microtubule stabilizing activity and low susceptibility to drug resistance mechanisms, including multidrug-resistant protein and P-glycoprotein .
In the US, ixabepilone is approved for use in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer after failure of an anthracycline and a taxane.
Angiogenesis Inhibition:
Sunitinib :
a dual inhibitor of the receptors for platelet-derived growth factor and vascular endothelial growth factor, has been investigated in a preliminary phase II trial in TNBC patients with metastatic disease who had received prior anthracycline and taxane therapy.
- Breast cancer that lacks expression of estrogen receptor/progesterone receptor, and overexpression of the human epidermal growth factor receptor 2 (HER2), or triple-negative breast cancer (TNBC), accounts for around 15–20% of breast cancers in the US.
- It typically carries a poorer prognosis than other breast cancer subgroups, with shorter periods of disease-free and overall survival. TNBC also has a propensity for visceral or central nervous system metastases
Neoadjuvant/Adjuvant Setting
Epidermal Growth Factor Receptor Inhibition
- A retrospective analysis of 1601 breast cancer patients showed that compared with other breast cancer subgroups, those with TNBC have a significantly higher risk of distant recurrence and death within 5 years of diagnosis.
- TNBC tend to have a better response to neoadjuvant chemotherapy than other subtypes.
SRC Kinase Inhibition:
In vitro studies have indicated that TNBC cell lines display greater sensitivity to growth inhibition by the multitarget kinase inhibitor, dasatinib, than luminal or HER2-overexpressed breast cancer cell lines.
Aberrant Deoxyribonucleic Acid Repair
Platinum Agents:
Triple-negative breast cancer cells exhibit an abundance of DNA aberrations, suggesting that their DNA repair mechanisms are defective. Consequently, these tumors may have an increased sensitivity to agents that cause inter-strand DNA breaks (e.g., platinum agents)